Does CVS–Aetna Spell the End of Business as Usual?

The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 378; no. 7; pp. 593 - 595
Main Author: Dafny, Leemore S
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 15.02.2018
Subjects:
Acquisitions & mergers
Antitrust
Drug stores
Health care policy
Market shares
Pharmaceutical industry
Pharmacy
Prescription drugs
Primary care
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMp1717137